table of content
1 Study Coverage
1.1 Neurodegenerative Drugs Product Introduction
1.2 Global Neurodegenerative Drugs Outlook 2017 VS 2022 VS 2028
1.2.1 Global Neurodegenerative Drugs Sales in US$ Million for the Year 2017-2028
1.2.2 Global Neurodegenerative Drugs Sales in Volume for the Year 2017-2028
1.3 United States Neurodegenerative Drugs Outlook 2017 VS 2022 VS 2028
1.3.1 United States Neurodegenerative Drugs Sales in US$ Million for the Year 2017-2028
1.3.2 United States Neurodegenerative Drugs Sales in Volume for the Year 2017-2028
1.4 Neurodegenerative Drugs Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.4.1 The Market Share of United States Neurodegenerative Drugs in Global, 2017 VS 2022 VS 2028
1.4.2 The Growth Rate of Neurodegenerative Drugs Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.5 Neurodegenerative Drugs Market Dynamics
1.5.1 Neurodegenerative Drugs Industry Trends
1.5.2 Neurodegenerative Drugs Market Drivers
1.5.3 Neurodegenerative Drugs Market Challenges
1.5.4 Neurodegenerative Drugs Market Restraints
1.6 Study Objectives
1.7 Years Considered
2 Market by Type
2.1 Neurodegenerative Drugs Market Segment by Type
2.1.1 NMDA
2.1.2 SSRIs
2.1.3 Dopamine Inhibitors
2.2 Global Neurodegenerative Drugs Market Size by Type
2.2.1 Global Neurodegenerative Drugs Sales in Value, by Type (2017, 2022 & 2028)
2.2.2 Global Neurodegenerative Drugs Sales in Volume, by Type (2017, 2022 & 2028)
2.2.3 Global Neurodegenerative Drugs Average Selling Price (ASP) by Type (2017, 2022 & 2028)
2.3 United States Neurodegenerative Drugs Market Size by Type
2.3.1 United States Neurodegenerative Drugs Sales in Value, by Type (2017, 2022 & 2028)
2.3.2 United States Neurodegenerative Drugs Sales in Volume, by Type (2017, 2022 & 2028)
2.3.3 United States Neurodegenerative Drugs Average Selling Price (ASP) by Type (2017, 2022 & 2028)
3 Market by Application
3.1 Neurodegenerative Drugs Market Segment by Application
3.1.1 Parkinson?s Disease
3.1.2 Huntington Disease
3.1.3 Amyotrophic Lateral Sclerosis
3.1.4 Alzheimer?s Disease
3.2 Global Neurodegenerative Drugs Market Size by Application
3.2.1 Global Neurodegenerative Drugs Sales in Value, by Application (2017, 2022 & 2028)
3.2.2 Global Neurodegenerative Drugs Sales in Volume, by Application (2017, 2022 & 2028)
3.3.3 Global Neurodegenerative Drugs Average Selling Price (ASP) by Application (2017, 2022 & 2028)
3.3 United States Neurodegenerative Drugs Market Size by Application
3.3.1 United States Neurodegenerative Drugs Sales in Value, by Application (2017, 2022 & 2028)
3.3.2 United States Neurodegenerative Drugs Sales in Volume, by Application (2017, 2022 & 2028)
3.3.3 United States Neurodegenerative Drugs Average Selling Price (ASP) by Application (2017, 2022 & 2028)
4 Global Neurodegenerative Drugs Competitor Landscape by Company
4.1 Global Neurodegenerative Drugs Market Size by Company
4.1.1 Top Global Neurodegenerative Drugs Manufacturers Ranked by Revenue (2021)
4.1.2 Global Neurodegenerative Drugs Revenue by Manufacturer (2017-2022)
4.1.3 Global Neurodegenerative Drugs Sales by Manufacturer (2017-2022)
4.1.4 Global Neurodegenerative Drugs Price by Manufacturer (2017-2022)
4.2 Global Neurodegenerative Drugs Concentration Ratio (CR)
4.2.1 Neurodegenerative Drugs Market Concentration Ratio (CR) (2017-2022)
4.2.2 Global Top 5 and Top 10 Largest Manufacturers of Neurodegenerative Drugs in 2021
4.2.3 Global Neurodegenerative Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.3 Global Neurodegenerative Drugs Manufacturing Base Distribution, Product Type
4.3.1 Global Neurodegenerative Drugs Manufacturers, Headquarters and Distribution of Producing Region
4.3.2 Manufacturers Neurodegenerative Drugs Product Type
4.3.3 Date of International Manufacturers Enter into Neurodegenerative Drugs Market
4.4 Manufacturers Mergers & Acquisitions, Expansion Plans
4.5 United States Neurodegenerative Drugs Market Size by Company
4.5.1 Top Neurodegenerative Drugs Players in United States, Ranked by Revenue (2021)
4.5.2 United States Neurodegenerative Drugs Revenue by Players (2020, 2021 & 2022)
4.5.3 United States Neurodegenerative Drugs Sales by Players (2020, 2021 & 2022)
5 Global Neurodegenerative Drugs Market Size by Region
5.1 Global Neurodegenerative Drugs Market Size by Region: 2017 VS 2022 VS 2028
5.2 Global Neurodegenerative Drugs Market Size in Volume by Region (2017-2028)
5.2.1 Global Neurodegenerative Drugs Sales in Volume by Region: 2017-2022
5.2.2 Global Neurodegenerative Drugs Sales in Volume Forecast by Region (2023-2028)
5.3 Global Neurodegenerative Drugs Market Size in Value by Region (2017-2028)
5.3.1 Global Neurodegenerative Drugs Sales in Value by Region: 2017-2022
5.3.2 Global Neurodegenerative Drugs Sales in Value by Region: 2023-2028
6 Segment in Region Level & Country Level
6.1 North America
6.1.1 North America Neurodegenerative Drugs Market Size YoY Growth 2017-2028
6.1.2 North America Neurodegenerative Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
6.1.3 United States
6.1.4 Canada
6.2 Asia-Pacific
6.2.1 Asia-Pacific Neurodegenerative Drugs Market Size YoY Growth 2017-2028
6.2.2 Asia-Pacific Neurodegenerative Drugs Market Facts & Figures by Region (2017, 2022 & 2028)
6.2.3 China
6.2.4 Japan
6.2.5 South Korea
6.2.6 India
6.2.7 Australia
6.2.8 China Taiwan
6.2.9 Indonesia
6.2.10 Thailand
6.2.11 Malaysia
6.3 Europe
6.3.1 Europe Neurodegenerative Drugs Market Size YoY Growth 2017-2028
6.3.2 Europe Neurodegenerative Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
6.3.3 Germany
6.3.4 France
6.3.5 U.K.
6.3.6 Italy
6.3.7 Russia
6.4 Latin America
6.4.1 Latin America Neurodegenerative Drugs Market Size YoY Growth 2017-2028
6.4.2 Latin America Neurodegenerative Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
6.4.3 Mexico
6.4.4 Brazil
6.4.5 Argentina
6.5 Middle East and Africa
6.5.1 Middle East and Africa Neurodegenerative Drugs Market Size YoY Growth 2017-2028
6.5.2 Middle East and Africa Neurodegenerative Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
6.5.3 Turkey
6.5.4 Saudi Arabia
6.5.5 UAE
7 Company Profiles
7.1 Novartis
7.1.1 Novartis Corporation Information
7.1.2 Novartis Description and Business Overview
7.1.3 Novartis Neurodegenerative Drugs Sales, Revenue and Gross Margin (2017-2022)
7.1.4 Novartis Neurodegenerative Drugs Products Offered
7.1.5 Novartis Recent Development
7.2 Pfizer
7.2.1 Pfizer Corporation Information
7.2.2 Pfizer Description and Business Overview
7.2.3 Pfizer Neurodegenerative Drugs Sales, Revenue and Gross Margin (2017-2022)
7.2.4 Pfizer Neurodegenerative Drugs Products Offered
7.2.5 Pfizer Recent Development
7.3 Merck Serono
7.3.1 Merck Serono Corporation Information
7.3.2 Merck Serono Description and Business Overview
7.3.3 Merck Serono Neurodegenerative Drugs Sales, Revenue and Gross Margin (2017-2022)
7.3.4 Merck Serono Neurodegenerative Drugs Products Offered
7.3.5 Merck Serono Recent Development
7.4 Biogen Idec
7.4.1 Biogen Idec Corporation Information
7.4.2 Biogen Idec Description and Business Overview
7.4.3 Biogen Idec Neurodegenerative Drugs Sales, Revenue and Gross Margin (2017-2022)
7.4.4 Biogen Idec Neurodegenerative Drugs Products Offered
7.4.5 Biogen Idec Recent Development
7.5 TEVA
7.5.1 TEVA Corporation Information
7.5.2 TEVA Description and Business Overview
7.5.3 TEVA Neurodegenerative Drugs Sales, Revenue and Gross Margin (2017-2022)
7.5.4 TEVA Neurodegenerative Drugs Products Offered
7.5.5 TEVA Recent Development
7.6 UCB
7.6.1 UCB Corporation Information
7.6.2 UCB Description and Business Overview
7.6.3 UCB Neurodegenerative Drugs Sales, Revenue and Gross Margin (2017-2022)
7.6.4 UCB Neurodegenerative Drugs Products Offered
7.6.5 UCB Recent Development
7.7 Boehringer Ingelheim
7.7.1 Boehringer Ingelheim Corporation Information
7.7.2 Boehringer Ingelheim Description and Business Overview
7.7.3 Boehringer Ingelheim Neurodegenerative Drugs Sales, Revenue and Gross Margin (2017-2022)
7.7.4 Boehringer Ingelheim Neurodegenerative Drugs Products Offered
7.7.5 Boehringer Ingelheim Recent Development
7.8 Sanofi
7.8.1 Sanofi Corporation Information
7.8.2 Sanofi Description and Business Overview
7.8.3 Sanofi Neurodegenerative Drugs Sales, Revenue and Gross Margin (2017-2022)
7.8.4 Sanofi Neurodegenerative Drugs Products Offered
7.8.5 Sanofi Recent Development
7.9 GlaxoSmithKline
7.9.1 GlaxoSmithKline Corporation Information
7.9.2 GlaxoSmithKline Description and Business Overview
7.9.3 GlaxoSmithKline Neurodegenerative Drugs Sales, Revenue and Gross Margin (2017-2022)
7.9.4 GlaxoSmithKline Neurodegenerative Drugs Products Offered
7.9.5 GlaxoSmithKline Recent Development
7.10 Livzon Pharmaceutical
7.10.1 Livzon Pharmaceutical Corporation Information
7.10.2 Livzon Pharmaceutical Description and Business Overview
7.10.3 Livzon Pharmaceutical Neurodegenerative Drugs Sales, Revenue and Gross Margin (2017-2022)
7.10.4 Livzon Pharmaceutical Neurodegenerative Drugs Products Offered
7.10.5 Livzon Pharmaceutical Recent Development
7.11 Haisco Pharmaceutical
7.11.1 Haisco Pharmaceutical Corporation Information
7.11.2 Haisco Pharmaceutical Description and Business Overview
7.11.3 Haisco Pharmaceutical Neurodegenerative Drugs Sales, Revenue and Gross Margin (2017-2022)
7.11.4 Haisco Pharmaceutical Neurodegenerative Drugs Products Offered
7.11.5 Haisco Pharmaceutical Recent Development
7.12 Jingxin Pharmaceutical
7.12.1 Jingxin Pharmaceutical Corporation Information
7.12.2 Jingxin Pharmaceutical Description and Business Overview
7.12.3 Jingxin Pharmaceutical Neurodegenerative Drugs Sales, Revenue and Gross Margin (2017-2022)
7.12.4 Jingxin Pharmaceutical Products Offered
7.12.5 Jingxin Pharmaceutical Recent Development
7.13 Dongcheng Biochemicals
7.13.1 Dongcheng Biochemicals Corporation Information
7.13.2 Dongcheng Biochemicals Description and Business Overview
7.13.3 Dongcheng Biochemicals Neurodegenerative Drugs Sales, Revenue and Gross Margin (2017-2022)
7.13.4 Dongcheng Biochemicals Products Offered
7.13.5 Dongcheng Biochemicals Recent Development
7.14 Hisun Pharmaceutical
7.14.1 Hisun Pharmaceutical Corporation Information
7.14.2 Hisun Pharmaceutical Description and Business Overview
7.14.3 Hisun Pharmaceutical Neurodegenerative Drugs Sales, Revenue and Gross Margin (2017-2022)
7.14.4 Hisun Pharmaceutical Products Offered
7.14.5 Hisun Pharmaceutical Recent Development
7.15 Luye Pharma
7.15.1 Luye Pharma Corporation Information
7.15.2 Luye Pharma Description and Business Overview
7.15.3 Luye Pharma Neurodegenerative Drugs Sales, Revenue and Gross Margin (2017-2022)
7.15.4 Luye Pharma Products Offered
7.15.5 Luye Pharma Recent Development
7.16 Ark Pharmaceutical
7.16.1 Ark Pharmaceutical Corporation Information
7.16.2 Ark Pharmaceutical Description and Business Overview
7.16.3 Ark Pharmaceutical Neurodegenerative Drugs Sales, Revenue and Gross Margin (2017-2022)
7.16.4 Ark Pharmaceutical Products Offered
7.16.5 Ark Pharmaceutical Recent Development
7.17 Kanghong Pharmaceutical
7.17.1 Kanghong Pharmaceutical Corporation Information
7.17.2 Kanghong Pharmaceutical Description and Business Overview
7.17.3 Kanghong Pharmaceutical Neurodegenerative Drugs Sales, Revenue and Gross Margin (2017-2022)
7.17.4 Kanghong Pharmaceutical Products Offered
7.17.5 Kanghong Pharmaceutical Recent Development
7.18 Huahai Pharmaceutical
7.18.1 Huahai Pharmaceutical Corporation Information
7.18.2 Huahai Pharmaceutical Description and Business Overview
7.18.3 Huahai Pharmaceutical Neurodegenerative Drugs Sales, Revenue and Gross Margin (2017-2022)
7.18.4 Huahai Pharmaceutical Products Offered
7.18.5 Huahai Pharmaceutical Recent Development
7.19 BORA PHARMACEUTICALS
7.19.1 BORA PHARMACEUTICALS Corporation Information
7.19.2 BORA PHARMACEUTICALS Description and Business Overview
7.19.3 BORA PHARMACEUTICALS Neurodegenerative Drugs Sales, Revenue and Gross Margin (2017-2022)
7.19.4 BORA PHARMACEUTICALS Products Offered
7.19.5 BORA PHARMACEUTICALS Recent Development
8 Industry Chain and Sales Channels Analysis
8.1 Neurodegenerative Drugs Industry Chain Analysis
8.2 Neurodegenerative Drugs Key Raw Materials
8.2.1 Key Raw Materials
8.2.2 Neurodegenerative Drugs Distributors
8.3 Neurodegenerative Drugs Production Mode & Process
8.4 Neurodegenerative Drugs Sales and Marketing
8.4.1 Neurodegenerative Drugs Sales Channels
8.4.2 Neurodegenerative Drugs Distributors
8.5 Neurodegenerative Drugs Customers
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
